Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Hong Qin

3PUBLICATIONS
15CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

Sort by Publication Date:
|Dec 05, 2022
Generation of a humanized afucosylated BAFF-R antibody with broad activity against human B-cell malignancies.

Zhenyuan Dong, Joo Y Song, Elana Thieme

|May 27, 2020
Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions.

Zhenyuan Dong, Wesley A Cheng, D Lynne Smith

|Sep 27, 2019
CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.

Hong Qin, Zhenyuan Dong, Xiuli Wang

Pageof 1

Frequent Collaborators

2 joint publications

Larry W Kwak

1 joint publications

Zhenyuan Dong

1 joint publications

Feng Wen

1 joint publications

Weili Xue

1 joint publications

Miriam Walter

1 joint publications

Fan Fei

1 joint publications

Jianming Xie

1 joint publications

Theano I Panagopoulou

1 joint publications

Chun-Wei Chen

1 joint publications

Joo Y Song

Frequent Collaborators

2 joint publications

Larry W Kwak

1 joint publications

Zhenyuan Dong

1 joint publications

Feng Wen

1 joint publications

Weili Xue

Top Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on : May 22, 2020

3.6K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on : Feb 16, 2015

21.9K
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on : Dec 17, 2019

15.9K
See more related videos

Top Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on : May 22, 2020

3.6K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on : Feb 16, 2015

21.9K
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on : Dec 17, 2019

15.9K
See more related videos